Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
61-75 of 3791 results
BioCryst gets additional NIAID funding to advance development of BCX4430
BioCryst Pharmaceuticals has announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised additional options to conduct Phase 1 clinical human safety trials of an intramuscular formulation of BCX4430, as well as efficacy studies in non-human primates to assess effective dose ranges and dose schedules.
Drug Research > Drug Discovery & Development > News
AstraZeneca releases top-line results from Phase III programme of lesinurad in gout patients
By PBR Staff Writer
AstraZeneca has released positive top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), as a combination therapy to treat patients with symptomatic gout.
Drug Research > Drug Discovery & Development > News
GlaxoSmithKline’s Ebola vaccine may enter clinical trials soon
By PBR Staff Writer
British drugmaker GlaxoSmithKline (GSK) spokesperson has said that its experimental Ebola vaccine may enter into clinical trial "later this year."
Drug Research > Drug Discovery & Development > News
Avillion doses first patients in Phase III bfore trial of BOSULIF to treat CML
Avillion, a co-developer of late-stage pharmaceutical assets, has announced that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014.
Drug Research > Drug Discovery & Development > News
TVM Life supports FAAH Pharma in new neuropathic pain treatment
By PBR Staff Writer
TVM Life Science Ventures VII has made an investment into FAAH Pharma to help the company continue the clinical development of a compound with the potential to treat neuropathic pain.
Drug Research > Drug Discovery & Development > News
Idera, TMA to advance clinical development of myositis treatment
By PBR Staff Writer
Idera Pharmaceuticals and The Myositis Association (TMA) have collaborated to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.
Drug Research > Drug Discovery & Development > News
Neurovance completes patient enrollment in HAL study for centanafadine to treat ADHD
By PBR Staff Writer
Neurovance, a US-based neuroscience-focused company has completed enrollment in a human abuse liability (HAL) study of centanafadine (formerly EB-1020), a new non-stimulant being developed to treat adults with attention deficit hyperactivity disorder (ADHD).
Drug Research > Drug Discovery & Development > News
Cannabis Science in final negotiations to set up first medical cannabis facilities in Canada
By PBR Staff Writer
Cannabis Science, a US-based company specializing in cannabis formulation-based drug development and related consulting, is in the final stages of launching a new joint venture (JV) company.
Drug Research > Drug Discovery & Development > News
Yabao, Changzhou Le Sun Pharmaceuticals to develop early-stage cancer drugs
By PBR Staff Writer
China-based Yabao Pharmaceutical has entered into a strategic partnership with Changzhou Le Sun Pharmaceuticals to co-develop Le Sun's leading PLK/PI3K dual inhibitor LS-008, which currently is under pre-clinical development.
Drug Research > Drug Discovery & Development > News
Daiichi Sankyo, Charleston to develop new hydrocodone products
Daiichi Sankyo and Charleston Laboratories, through its wholly owned subsidiary LOCL Pharma, have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories' novel hydrocodone combination products, including CL-108, being studied for the treatment of moderate to severe acute pain as well as the reduction of Opioid-Induced Nausea and Vomiting (OINV).
Drug Research > Drug Discovery & Development > News
Soligenix secures additional NIAID funding to advance development of OrbeShield in GI ARS
Soligenix (SNGX), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, has announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShieldTM (oral beclomethasone 17,21-dipropionate or oral BDP).
Drug Research > Drug Discovery & Development > News
Cortice acquires rights to new neurological disease therapeutic, development platform
By PBR Staff Writer
US-based drug development firm Cortice Biosciences has acquired exclusive commercial rights to a portfolio of small molecule drug candidates to treat diseases associated with cognitive impairment.
Drug Research > Drug Discovery & Development > News
Incyte, Genentech to assess combination of two new cancer immunotherapies
By PBR Staff Writer
US-based biopharmaceutical firm Incyte has entered into a clinical trial agreement with Genentech to assess the combination of two new cancer immunotherapies for patients with non-small cell lung cancer (NSCLC).
Drug Research > Drug Discovery & Development > News
PCI announces definitive agreement to acquire Penn Pharma
Packaging Coordinators (PCI) is pleased to announce that it has reached a definitive agreement to acquire Penn Pharmaceutical Services Limited (Penn Pharma).
Drug Research > Drug Discovery & Development > News
Quark reports favorable results from Phase II clinical trial evaluating investigational siRNA QPI-1002
Quark Pharmaceuticals has reported data from a randomized, double-blinded, placebo-controlled multicenter Phase II clinical trial (QRK.006B; ClinicalTrials.gov identifier: NCT00802347) of QPI-1002, a synthetic chemically modified siRNA acting to reduce p53 RNA and protein levels, for the prophylaxis of delayed graft function (DGF) in deceased donor kidney transplant patients.
Drug Research > Drug Discovery & Development > News
61-75 of 3791 results